| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2874863 | The Annals of Thoracic Surgery | 2013 | 6 Pages |
Abstract
The LVAD supported HTx recipients have better posttransplant survival than patients after all other mechanical support pathways. Survival after HTx is optimized when ECMO or biventricular assist device support can be transitioned to LVAD-only support. Our findings should aid clinical decision making and inform organ allocation policy development intended to maximize societal benefits of HTx.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Tara MD, MS, Jill MD, Brian S. PhD, Frederick A. MD, James M. MD, Steven W. MD, Matthew S. MD, Howard K. MD, PhD,